Phenytoin administration in the newborn and infant

Federico Sicca, Annarita Contaldo, Elisabeth Rey, Olivier Dulac

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalBrain and Development
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Phenytoin
Newborn Infant
Seizures
Status Epilepticus
Intravenous Administration
Oral Administration
Therapeutics
Epilepsy
Safety

Keywords

  • Epilepsy
  • Infant
  • Newborn
  • Phenytoin
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Phenytoin administration in the newborn and infant. / Sicca, Federico; Contaldo, Annarita; Rey, Elisabeth; Dulac, Olivier.

In: Brain and Development, Vol. 22, No. 1, 01.01.2000, p. 35-40.

Research output: Contribution to journalArticle

Sicca, Federico ; Contaldo, Annarita ; Rey, Elisabeth ; Dulac, Olivier. / Phenytoin administration in the newborn and infant. In: Brain and Development. 2000 ; Vol. 22, No. 1. pp. 35-40.
@article{83b73241a9c54851a54b395b21925d0b,
title = "Phenytoin administration in the newborn and infant",
abstract = "To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55{\%} of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1{\%}. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1{\%} of the patients, and 43.6{\%} had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Epilepsy, Infant, Newborn, Phenytoin, Status epilepticus",
author = "Federico Sicca and Annarita Contaldo and Elisabeth Rey and Olivier Dulac",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0387-7604(99)00110-2",
language = "English",
volume = "22",
pages = "35--40",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Phenytoin administration in the newborn and infant

AU - Sicca, Federico

AU - Contaldo, Annarita

AU - Rey, Elisabeth

AU - Dulac, Olivier

PY - 2000/1/1

Y1 - 2000/1/1

N2 - To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.

AB - To evaluate the efficacy and safety of phenytoin (PHT) in the treatment of situation-related seizures and epilepsies in the newborn and infant; the clinical histories of 82 patients were retrospectively reviewed. Sixty patients received for status epilepticus (SE), intravenous PHT followed by long-term oral administration for 27 of them. The other 22 patients had oral treatment only. Intravenous administration made 55% of these patients seizure-free, whereas oral administration produced lasting seizure control in only 9.1%. During chronic oral treatment, it was most difficult to obtain adequate plasma concentrations in 69.1% of the patients, and 43.6% had side effects, most of which were related to very high plasma concentrations. In conclusion, in the first 2 years of life, intravenous administration of PHT is useful for SE, but oral treatment is poorly effective with difficulty to achieve appropriate and stable therapeutic plasma concentrations, and with frequent side effects. Copyright (C) 2000 Elsevier Science B.V.

KW - Epilepsy

KW - Infant

KW - Newborn

KW - Phenytoin

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=0033969340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033969340&partnerID=8YFLogxK

U2 - 10.1016/S0387-7604(99)00110-2

DO - 10.1016/S0387-7604(99)00110-2

M3 - Article

VL - 22

SP - 35

EP - 40

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 1

ER -